Metronidazole Basi (Metronidazole)

Metronidazole penetrates susceptible cells and is reduced by microbial enzymes to form nitro radical anions. These reactive intermediates damage DNA by causing strand breaks and loss of helical structure, which blocks nucleic acid synthesis and leads to cell death. The mechanism is selective for anaerobic bacteria and certain protozoa that possess the necessary reductive pathways.

The dosage of Metronidazole Basi is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals calculate the appropriate intravenous infusion rate and duration to achieve therapeutic levels while minimizing toxicity.

Safety data for Metronidazole during pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is essential, it should be administered under close medical supervision, and breastfeeding mothers should be advised of the potential for drug excretion in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metronidazole is a nitroimidazole that offers rapid bactericidal activity against obligate anaerobes, often with fewer dosing adjustments than beta‑lactams in renal impairment. Alternatives such as clindamycin or carbapenems may be used, but Metronidazole provides a cost‑effective option with a well‑characterised safety profile when the pathogen is known to be susceptible.

Metronidazole Basi should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Maintaining these conditions preserves drug stability and potency throughout its shelf life.

Metronidazole Basi is given by intravenous infusion under the supervision of qualified healthcare personnel. The infusion rate and duration are set by the prescriber according to the infection being treated, patient weight, and clinical response, ensuring therapeutic drug concentrations are achieved safely.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions (anaphylaxis), hepatotoxicity, and hematologic abnormalities such as neutropenia. Patients should be monitored for neurological symptoms, liver function changes, and signs of hypersensitivity, and therapy should be discontinued if severe reactions occur.

Metronidazole Basi is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is advised for individuals with severe hepatic impairment, those taking disulfiram, and patients with a history of seizures or peripheral neuropathy, unless the benefits outweigh the risks.